The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C

Size: px
Start display at page:

Download "The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C"

Transcription

1 The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

2 Prevalence of diabetes in Total number of people with diabetes (age 20-79) Prevalence of diabetes (age 20-79) 285 million 438 million 6.6 % 7.8 % IDF diabetes atlas, 4th edition, 2009

3 Estimated life years lost among those with Diabetes Seshasai, NEJM ;364(9):

4 Diabetes doubles the risk of vascular disease Data from 528,877 participants in 103 studies (adjusted for age sex, cohort, SBP, smoking, BMI) Outcome Number of cases HR (95% CI) I 2 (95% CI) Coronary heart disease ( ) 64 (54-71) Coronary death ( ) 41 (24-54) Non-fatal myocardial infarction ( ) 37 (19-51) Cerebrovascular disease ( ) 42 (25-55) Ischaemic stroke ( ) 1 (0-20) Haemorrhagic stroke ( ) 0 (0-26) Unclassified stroke ( ) 33 (12-48) Other vascular deaths ( ) 0 (0-26) Hazard ratio (diabetes vs. no diabetes) Lancet Jun 26;375(9733):

5 The dyslipidemia of intra-abdominal obesity and Type 2 diabetes VLDL LDL HDL Normal Insulin resistance VLDL triglycerides VLDL apo B LDL apo B Particle number Particle size (small,dense) HDL cholesterol Particle number Particle size (small,dense)

6 Structure of Lipoproteins Phospholipid Free cholesterol Triglyceride Apolipoprotein Cholesteryl ester

7 Atherogenic Particles MEASUREMENTS: Apolipoprotein B or Non-HDL-C VLDL VLDL R IDL LDL Small, dense LDL TG-rich lipoproteins

8 HDL can be categorised by shape, size & composition Particle shape Discoidal Apolipoprotein composition eg A-I HDL A-I/A-II HDL E-containing HDL Spherical Particle size Pre-beta HDL HDL 2b HDL 2a HDL 3a HDL 3b HDL 3c Adapted from Barter PJ. Atheroscler Suppl. 2002;3:39 47.

9 Why Does HDL Protect? Beyond Cholesterol Transport antiinflammatory antiapoptotic endothelial repair protection against oxidation antithrombotic modulation of endothelial function Cholesterol Transport HDL cholesterylester donor

10 What is the best measure of atherogenic risk LDL-C, Non-HDL-C or apo B? Associations of major lipids and apoproteins with CHD from data over 125 studies HR 95% Cl LDL-C, per 0.84 mmol/l Non-HDL-C, per 1.10 mmol/l Apo B, per 29mg/dl HDL-C, per 0.38 mmol/l Apo A-I, per 29mg/dl Non HDL-C/HDL-C, per 1.53 Unit Apo B/ Apo A-I, per 0.27 Unit TG, per 60% change Adjusted for confounding factors and lipid markers The Emerging Risk factors Collaboration JAMA 2009;302;

11 Recommendations for lipid analyses as treatment target in the prevention of CVD Consensus guidelines EHJ 2012

12 Mean change from baseline (%) ANDROMEDA study Comparison of Effectiveness of Rosuvastatin vs Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/l) and Low-Density Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus <LDL Cholesterol> <Triglyceride> <Apo B> 8 weeks 16 weeks 8 weeks 16 weeks 8 weeks 16 weeks 0 RSV ATV 10 mg 10 mg RSV ATV 20 mg 20 mg 0 RSV ATV 10 mg 10 mg RSV ATV 20 mg 20 mg 0 RSV ATV 10 mg 10 mg RSV ATV 20 mg 20 mg N= N= # - 17 N= N= N= N= * N= N=227 N= N= * - 31 N= * N= * RSV = rosuvastatin, ATV = atorvastatin *p<0.001 RSV 10 mg vs ATV 10 mg ; RSV 20 mg vs ATV 20 mg #p=0.032 RSV 10 mg vs ATV 10 mg Betteridge DJ et al. Am J Cardiol.2007 Oct 15;100(8):

13 LSM change from baseline in LDL-C (%) CORALL study A study to COmpare the effect of Rosuvastatin (10 40 mg) with Atorvastatin (20 80 mg) on apo B/apo A-1 ratio in patients with type 2 diabetes mellitus and dyslipidaemia 6 weeks 12 weeks 18 weeks 0 RSV 10 mg ATV 20 mg RSV 20 mg ATV 40 mg RSV 40 mg ATV 80 mg n=130 n=132 n=130 n=132 n=130 n= * * 53.6 ** RSV=rosuvastatin (n=130); ATV=atorvastatin (n=132) LSM=least-squares mean, *p<0.05 vs ATV; **p<0.01 vs ATV 47.8 B. H. R. WOLFFENBUTTEL et al. Journal of Internal Medicine 2005; 257:

14 Do statins work in Diabetes Mellitus?

15 Primary Prevention Trials of Lipid-Altering Therapy Including Patients with Diabetes Trial Diabetic,* n Total N in Study Lipid-Altering Drug, mg/d CHD* Risk vs Placebo in Diabetic Patients, % CARDS 2,838 2,838 Atorvastatin (p=.001) AFCAPS 155 6,605 Lovastatin (NS) HPS 2,912 7,150 Simvastatin (p=.0003) ASCOT 2,532 10,305 Atorvastatin (NS) PROSPER 623 5,804 Pravastatin (NS) HHS 135 4,081 Gemfibrozil (NS) * By history Prospective trial in diabetic subjects; others are subgroup analyses Mean 30 mg/d Type 1 or 2 diabetes Bays H et al. Future Cardiology 2005;1: Colhoun HM et al. Lancet 2004;364: Downs JR et al. JAMA 1998;279: HPS Collaborative Group. Lancet 2003;361: Sever PS et al. Lancet 2003;361: Shepherd J et al. Lancet 2002;360: Koskinen P et al. Diabetes Care 1992;15:

16 Median LDL-C (mmol/l) Cumulative Hazard(%) Lower LDL-C reduces risk for CHD in DM patients <CARDS> 4 3 LDL Cholesterol (mmol/l) Average difference 40% (95% CI -41 to -39) 1.20 mmol/l; P< Placebo The Primary Endpoint Major CV Events Including Stroke Relative Risk Reduction 37% (95% CI, - 52 to -17) P = Placebo 127 events 2 1 Atorvastatin 10mg 5 Atorvastatin 10mg 83 events Years Years * CARDS: Collaborative Atorvastatin Diabetes Study Placebo 1410 Atorvastatin Colhoun HM et al. Lancet 2004;364:

17 LDL-C lowering efficacy on FDA website

18 Atherosclerosis & the Diabetic Patient Vascular complication associated with type 2 diabetes are the major clinical problems facing patients. 1 Atherosclerosis develops much earlier and progresses more rapidly in diabetic patients than non-diabetics. 1 Mortality rates from coronary heart disease are two- to fourfold higher in diabetic patients than in non-diabetics. 1 Complication of atherosclerosis cause most morbidity & mortality in patients with diabetes. 2 Since most patients with diabetes die from complication of atherosclerosis, they should receive intensive preventive interventions proven to reduce their cardiovascular risk. 2 1) Steiner G. Diabetes and Vascular Disease Research 2007; 4: ) Beckman et al. JAMA 2002; 287:

19 Development of an Atherosclerotic Lesion Process Endothelial cell dysfunction Endothelial cell activation Inflammation Proteolysis Apoptosis Lipidcore and fibrous- cap formation Angiogenesis Thrombosis Blood Endothelial cell VCAM1, ICAM1, and selectins Monocyte recruitment Thin fibrous cap Smooth Fibrin Platelet Thrombus muscle Nitric oxide production cell Tissue factor Cholesterol LDL Collagen fibril T cell MMP Lipid-rich necrotic core Foam cell Internal α v β 3 - integrin Elastic lamina New blood vessel Adapted with permission from Sanz J, et al. Nature. 2008;451:

20 2.0 Relationship between achieved LDL C and change in PAV 1.5 CAMELOT 2 Placebo REVERSAL 1 Pravastatin 40mg Change in Percent Atheroma Volume* STRADIVARIUS 6 Placebo REVERSAL 1 Atorvastatin 80mg ASTEROID 4 Rosuvastatin 40mg A-PLUS 3 Placebo ILLUSTRATE 5 Atorvastatin + Placebo Progression Regression -1.0 SATURN 7 Atorvastatin 80mg -1.5 SATURN 7 Rosuvastatin 40mg Achieved LDL-C (mg/dl) Summary of trials employing IVUS to measure changes in atheroma burden. A-PLUS, CAMELOT, ILLUSTRATE and STRADIVARIUS investigated non-statin therapies but included placebo arms who received background statin therapy (62%, 80%, 84%, 100% and 82% respectively). In ILLUSTRATE atorvastatin was initiated at 10mg during the run-in period and dose titrated up to 80mg to a target LDL-C within 15mg/dL of 100mg/dL. The average dose was 23mg. Patients then remained on this dose during the study. LDL-C levels in CAMELOT are baseline and in A-PLUS are calculated from change from baseline. *Median change in PAV from ASTEROID, REVERSAL & SATURN; LS mean change in PAV from A-PLUS, CAMELOT, ILLUSTRATE & STRADIVARIUS. 1) Nissen S et al. JAMA 2004; 291: ; 2) Nissen S et al. JAMA 2004; 292: ; 3) Tardif J et al. Circulation 2004; 110: ; 4) Nissen S et al. JAMA 2006; 295: ; 5) Nissen S et al. N Engl J Med 2007; 356: ; 6) Nissen S et al. JAMA 2008; 299: ; 7) Nicholls SJ et al. New Eng J. Med. 2011: DOI: /NEJMoa

21 On-Treatment LDL-C at 24months (mg/dl) Mean intima- Media Thickness of carotid artery (mm) Atherosclerosis regression: what is the most important thing? <ENHANCE Trial> P< Difference from baseline at 24months P= mg/dl n=363 Difference 52 mg/dl mm mm n= 363 n= Simvastatin 80 mg 141 mg/dl n= 357 Simvastatin 80 mg Ezetimibe 10 mg Simvastatin 80 mg Simvastatin 80 mg Ezetimibe 10 mg ENHANCE: Ezetimibe and Simvastatin in Hypercholesterolmia Enhances Atherosclerosis Regression Klastelein JJ et al. N. Engl. J. Med. 2008;358:

22 Percent Change from Baseline Percent Change from Baseline Atherosclerosis regression: what is the most important thing? <ARBITER 6-HALTS> 25 HDL-C 0 LDL-C 20 Statin+Niacin HDL-C 18.4% at 14 months(p<0.001) -10 Statin+Niacin Statin+Ezetimibe Statin+Ezetimibe LDL-C 19.2% at 14months(P=0.01) Months ARBITER 6-HALTS: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 HDL and LDLTreatment Strategies. Months N Engl J Med Nov 26;361(22):

23 Change from Baseline in Mean Carotid Intima-Media Thickness (mm) Atherosclerosis regression: Manage not only LDL-C but also HDL-C <ARBITER 6-HALTS> Primary endpoint (The change from baseline in the mean common cimt after 14 months) Statin+Ezetimibe P=0.003* Statin+Niacin The P value is given for the comparison of repeated measures of the carotid intima-media thickness over 14-month period. Months 14 N Engl J Med Nov 26;361(22):

24 Relationships Between Change in Percent Atheroma Volume and LDL-C, HDL-C, LDL-C/HDL-C from REVERSAL, CAMELOT, ACTIVATE, ASTEROID * PAV: Percent atheroma volume Nicholls S et al. JAMA 2007; 297(5):

25 LS mean % change from baseline STELLAR results - LDL-C/HDL-C ratio Dose (mg) Rosuvastatin Atorvastatin Simvastatin Pravastatin n=156 n=158 n=154 n=156 n=165 n=162 n=158 n=160 n=164 n=161 Dose (mg) * * * * * * * -60 * p<0.002 vs Rosuvastatin10mg STELLAR study ; 2268 hypercholesterolemic subjects randomized to the rosuvastatin, atorvastatin, simvastatin, and pravastatin groups and followed-up for 6 weeks. Jones PH et al. Clin Ther 2004;26:

26 The same LDL-C reduction but the different effect for atherosclerosis (REVERSAL trial) Progression Regression The solid line indicates the relationship between mean change in low-density lipoprotein cholesterol and change in atheroma volume from linear regression analysis. The dash lines indicate the upper and lower 95% confidence limits for the mean values. Ref) 1. Nissen S. JAMA, March 3, 2004 Vol 291, No. 9

27 Mean change from baseline (%) Percent change from baseline(%) ARTMAP study Comparison of Effect of Atorvastatin (20mg) Versus Rosuvastatin (10mg) Therapy on Mild Coronary Atherosclerosis Plaque for Korean patients <LDL Cholesterol> 0 RSV 10 mg ATV 20 mg <Primary endpoint : TAV> 0 RSV 10 mg ATV 20 mg P= * P= * Analysis of covariance Ref) Lee CW. et al. Am J Cardiol Jun 15:109(12)

28 Atherosclerosis and CV outcome

29 Level of plaque regression is associated with CV outcome? Progression Compensatory concentric expansion maintains constant lumen Expansion overcome lumen starts to narrow Normal vessel Minimal CAD Moderate CAD Severe CAD Regression

30 Survival Baseline Plaque Burden and CV events Survival from cardiovascular events (death, myocardial infarction, and coronary revascularization) in 4137 patients in 6 clinical trials that used IVUS stratified according to quartiles (Q) of percent atheroma volume at baseline Q1 Q2 Q3 Q Days CV=cardiovascular; MI=myocardial infarction Ref) Nicholls SJ et al. J Am Coll Cardiol 2010;55:

31 Regression and Outcomes Atorvastatin vs Pravastatin Ref) 1. Nissen S. JAMA, March 3, 2004 Vol 291, No Cannon CP et al.n Engl J Med Apr 8;350(15):

32 Cumulative Incidence Rosuvastatin reduced the risk for major CV event JUPITER primary endpoint HR 0.56, 95%CI P < Number Needed to Treat to prevent The occurrence of one primary endpoint (NNT) = 25 Placebo Relative risk reduction 44% yrs 0.02 Rosuvastatin 20mg Number at Risk CRESTOR Placebo Primary Endpoint : MI, Stroke, UA/Revascularization, CV Death Follow-up (years) 8,901 8,631 8,412 6,540 3,893 1,958 1, ,901 8,621 8,353 6,508 3,872 1,963 1, Ridker P et al. N Eng J Med 2008;359:

33 Cumulative Incidence Moreover Rosuvastatin reduced all cause mortality in primary prevention JUPITER : All cause mortality HR 0.80, 95%CI P= 0.02 Rosuvastatin 20mg Placebo Relative risk reduction 20% Follow-up (years) Number at Risk CRESTOR 8,901 8,847 8,787 6,999 4,312 2,268 1,602 1, Placebo 8,901 8,852 8,775 6,987 4,319 2,295 1,614 1, *JUPITER secondary endpoints Ridker P et al. N Eng J Med 2008 vol 359

34 Safety: New onset of diabetes

35 Statins & HbA1c levels 1. Removal of the recommendation for routine monitoring of liver enzymes 2. Reports of increased blood glucose and glycosylated hemoglobin (HbA1c) levels 3. New information about reversible cognitive adverse effects 4. New contraindications and dose limitations

36 Statin and new onset of diabetes (NOD) meta-analysis Naveed Sattar et al., Lancet 2010;375:735-42

37 Age, independent risk factor for statin-induced NOD BMI Age Δ LDLc Meta-regression Age, p = BMI, p = Δ LDLc, p = Naveed Sattar et al., Lancet 2010;375:735-42

38 Risk for diabetes in participants with and without diabetes risk factor*(jupiter) *Metabolic Syndrome, IFG, Obesity, HbA1c > 6% at entry Almost all the excess risk of diabetes with rosuvastatin group occurred in participants with baseline evidence of IFG Ridker et al. Lancet 2012;380:565-71

39 Patients with new onset diabetes (%) Incident of diabetes according to baseline clinical predictors in the TNT trial Characteristic absent Characteristic present Fasting glucose >100 mg/dl Triglycerides >150 mg/dl BMI >30kg/m 2 History of hypertension Waters DD. Et al. JACC. 2011;57(14):

40 Prognosis of Patients with New-Onset T2DM TNT, IDEAL and SPARCL TNT, IDEAL and SPARCL Atorvastatin 80 mg groups With new-onset T2DM Without newonset T2DM Diabetes at baseline* With new-onset T2DM Without newonset T2DM Diabetes at baseline* Incidence of MCVE n / N (%) 157 / 1,387 (11.3%) 1,884/ 17,472 (10.8%) 832 / 4,761 (17.5%) 76 / 756 (10.1%) 867 / 8,684 (10.0%) 358 / 2,359 (15.2%) Univariate analysis** (HR=1.03, 95% CI , p=0.83) (HR=0.90, 95% CI , p=0.59) Multivariate analysis** (HR=1.02, 95% CI , p=0.69) (HR=0.87, 95% CI , p=0.49) *Patients were excluded from the new-onset T2DM study **MCVEs in patients with and without new-onset T2DM were assessed with an extensive time-dependent Cox proportional hazard analysis Waters DD et al. JACC. 2011;

41 ADA recommendation (2013) Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for diabetic patients: With overt CVD (A) Without CVD who are over the age of 40 & have one or more other CVD risk factors (A) Diabetes Care 36, Suppl 1, S11-65, 2013

42 Summary Diabetes increases risk of cardiovascular event and causes atherogenic dyslipidemia (TG, small dense LDL, HDL ) The vascular disease is main cause of death in diabetes patient, so managing atherosclerosis is essentially needed and rosuvastatin has a strong evidence in this area The cardiovascular and mortality benefits of statin therapy exceed the risk for diabetes, including subjects at high risk of developing diabetes.

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

Cottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?

Cottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,

More information

Changing lipid-lowering guidelines: whom to treat and how low to go

Changing lipid-lowering guidelines: whom to treat and how low to go European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor

More information

Lessons from Recent Atherosclerosis Trials

Lessons from Recent Atherosclerosis Trials Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD

More information

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Dyslipedemia New Guidelines

Dyslipedemia New Guidelines Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

Copyright 2017 by Sea Courses Inc.

Copyright 2017 by Sea Courses Inc. Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Landmark Clinical Trials.

Landmark Clinical Trials. Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug

More information

Atherosclerosis Regression An Overview of Recent Findings & Issues

Atherosclerosis Regression An Overview of Recent Findings & Issues Atherosclerosis Regression An Overview of Recent Findings & Issues 13th Angioplasty Summit 2008 Cheol Whan Lee, MD University of Ulsan, Asan Medical Center, Seoul, Korea CardioVascular Research Foundation

More information

Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC. Cardiovascular Center, Korea University Guro Hospital

Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC. Cardiovascular Center, Korea University Guro Hospital Novel Statin Strategy to Prevent Atherosclerotic Cardiovascular Disease in Diabetic Patients-Curtailing Heart Attack : Korean Data and JUPITER again in spotlight Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI,

More information

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

More information

Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering

Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering Matthew I. Worthley MB BS, PhD, FRACP, FCSANZ, FACC Senior Lecturer/ Interventional Cardiologist University

More information

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E

More information

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Hyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE

Hyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

ZEUS Trial ezetimibe Ultrasound Study

ZEUS Trial ezetimibe Ultrasound Study Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?

10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk? Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease. 1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association

More information

Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP

Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular

More information

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

Weigh the benefit of statin treatment: LDL & Beyond

Weigh the benefit of statin treatment: LDL & Beyond Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients

More information

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.

More information

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice 2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine

More information

Controversies in Lipid Therapy: Is there any value in adjusting HDL levels?

Controversies in Lipid Therapy: Is there any value in adjusting HDL levels? Controversies in Lipid Therapy: Is there any value in adjusting HDL levels? Sergio Fazio, MD, PhD Cornelius Vanderbilt Chair of Cardiovascular Medicine and Professor of Medicine, Pathology, Immunology,

More information

Introduction. Objective. Critical Questions Addressed

Introduction. Objective. Critical Questions Addressed Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Lipids: new drugs, new trials, new guidelines

Lipids: new drugs, new trials, new guidelines Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University

More information

Is it an era for statin for life?

Is it an era for statin for life? Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for

More information

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

More information

New Guidelines in Dyslipidemia Management

New Guidelines in Dyslipidemia Management The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

In-Ho Chae. Seoul National University College of Medicine

In-Ho Chae. Seoul National University College of Medicine The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:

More information

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA) Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Il rischio residuo nella persona con diabete: come individuarlo e come trattarlo?

Il rischio residuo nella persona con diabete: come individuarlo e come trattarlo? Il rischio residuo nella persona con diabete: come individuarlo e come trattarlo? Alberto Zambon University of Padova - Italy DISCLOSURE - CONFLICT OF INTEREST Prof. A. Zambon reports having received grants,

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

Cholesterol Treatment Update

Cholesterol Treatment Update Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

STATINS FOR PAD Long - term prognosis

STATINS FOR PAD Long - term prognosis STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest

More information

Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane

Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)

More information

Prof. John Chapman, MD, PhD, DSc

Prof. John Chapman, MD, PhD, DSc Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris

More information

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical

More information

Qué factores de riesgo lipídicos debemos controlar? En qué medida?

Qué factores de riesgo lipídicos debemos controlar? En qué medida? Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk

More information

PCSK9 Inhibitors and Modulators

PCSK9 Inhibitors and Modulators PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s

More information

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Methods. Background and Objectives STRADIVARIUS

Methods. Background and Objectives STRADIVARIUS STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau

More information

New Guidelines in Dyslipidemia Management

New Guidelines in Dyslipidemia Management The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical

More information

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,

More information

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

More information

Eyes on Korean Data: Lipid Management in Korean DM Patients

Eyes on Korean Data: Lipid Management in Korean DM Patients Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People

More information

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015 Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have

More information

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict

More information

Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist

Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist 1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information